Aberrant fibroblast growth factor receptor signaling in bladder and other cancers

Chaffer, Christine L., Dopheide, Bonnie, Savagner, Pierre, Thompson, Erik W., & Williams, Elizabeth D. (2007) Aberrant fibroblast growth factor receptor signaling in bladder and other cancers. Differentiation, 75(9), pp. 831-842.

View at publisher


Fibroblast growth factors (FGFs) are potent mitogens, morphogens, and inducers of angiogenesis, and FGF signaling governs the genesis of diverse tissues and organs from the earliest stages. With such fundamental embryonic and homeostatic roles, it follows that aberrant FGF signaling underlies a variety of diseases. Pathological modifications to FGF expression are known to cause salivary gland aplasia and autosomal dominant hypophosphatemic rickets, while mutations in FGF receptors (FGFRs) result in a range of skeletal dysplasias. Anomalous FGF signaling is also associated with cancer development and progression. Examples include the overexpression of FGF2 and FGF6 in prostate cancer, and FGF8 overexpression in breast and prostate cancers. Alterations in FGF signaling regulators also impact tumorigenesis, which is exemplified by the down-regulation of Sprouty 1, a negative regulator of FGF signaling, in prostate cancer. In addition, several FGFRs are mutated in human cancers (including FGFR2 in gastric cancer and FGFR3 in bladder cancer). We recently identified intriguing alterations in the FGF pathway in a novel model of bladder carcinoma that consists of a parental cell line (TSU-Pr1/T24) and two sublines with increasing metastatic potential (TSU-Pr1-B1 and TSU-Pr1-B2), which were derived successively through in vivo cycling. It was found that the increasingly metastatic sublines (TSU-Pr1-B1 and TSU-Pr1-B2) had undergone a mesenchymal to epithelial transition. FGFR2IIIc expression, which is normally expressed in mesenchymal cells, was increased in the epithelial-like TSU-Pr1-B1 and TSU-Pr1-B2 sublines and FGFR2 knock-down was associated with the reversion of cells from an epithelial to a mesenchymal phenotype. These observations suggest that modified FGF pathway signaling should be considered when studying other cancer types.

Impact and interest:

29 citations in Scopus
Search Google Scholar™
47 citations in Web of Science®

Citation counts are sourced monthly from Scopus and Web of Science® citation databases.

These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.

Citations counts from the Google Scholar™ indexing service can be viewed at the linked Google Scholar™ search.

ID Code: 72510
Item Type: Journal Article
Refereed: Yes
Additional Information: Cited By (since 1996):42 Export Date: 6 May 2014 Source: Scopus PubMed ID: 17697126
Additional URLs:
Keywords: Bladder carcinoma, FGF receptor, Fibroblast growth factor, Metastasis, TSU-Pr1
DOI: 10.1111/j.1432-0436.2007.00210.x
ISSN: 0301-4681
Divisions: Current > QUT Faculties and Divisions > Faculty of Health
Deposited On: 03 Jun 2014 04:04
Last Modified: 17 Jun 2014 02:22

Export: EndNote | Dublin Core | BibTeX

Repository Staff Only: item control page